News

Nanomerics licenses North American rights to NM133

Nanomerics today announced that it has licensed the North American rights to NM133 for the treatment of dry eye to IACTA Pharmaceuticals.

iacta logoIACTA Pharmaceuticals, Inc., a privately held pharmaceutical company, has acquired the North American rights to develop and commercialize NM133, an investigational medicine designed to help treat dry eye.

Nanomerics to Attend Biotech Showcase in San Francisco - 9th - 11th January 2017

Nanomerics is pleased to announce that Nanomerics’ Chief Scientific Officer, Professor Ijeoma F. Uchegbu, will again be attending Biotech Showcase (co-located with the JP Morgan Healthcare Conference) in San Francisco, CA, USA from the 9th - 11th January 2017. If you wish to meet with with Professor Uchegbu, please get in touch (Contact) and we will arrange a meeting.

Meet Nanomerics at Bio Europe 2016

bioeurope logoNanomerics’ Chief Scientific Officer, Professor Ijeoma F.Uchegbu will be attending Bio Europe 2016 in Köln, Germany (7th - 9th November 2016).  If you would like to meet Prof Uchegbu in Köln, please get in touch

Nanomerics CSO Prof Uchegbu wins Innovative Science Award

At the recent annual International APS PharmSci conference organised by the Academy of Pharmaceutical Sciences, Professor Ijeoma Uchegbu was awarded the Innovative Science Award, sponsored by GSK for her work on translating science into practice.

Nanomerics Attending and Presenting at Biotrinity 2016

biotrinity logoNanomerics Chief Scientific Officer - Professor Ijeoma F. Uchegbu - will be attending Biotrinity on the 25th and 26th of April 2016.  If you would like to meet Professor Uchegbu, please contact us to set up a meeting.  Nanomerics will also be presenting on the company’s vision, achievements and progress at Biotrinity London.

Meet Nanomerics at BioEuropeSpring 2016

Nanomerics will be attending the BioEurope Spring meeting in Stockholm from April 4 -6 2016. Nanomerics will be providing an update on recent developments of its lead products (NM0133, NM0147, and NM0127) as well as its capabilities for the delivery of biologics and advanced nucleic acid therapies, for example to the brain.

Nanomerics Molecular Envelope Technology safety confirmed

Nanomerics is pleased to announce a major milestone in toxicology testing of its Molecular Envelope Technology has been completed.  

New Publication Demonstrates the Utility of Nanomerics’ Molecular Envelope Technology (MET) in the Treatment of Experimental Brain Tumours

Nanomerics’ scientists have demonstrated that encapsulating chemotherapy drugs within Nanomerics’ MET nanoparticles diverts the drug from the bone marrow, while enabling higher levels of drug to access the brain.  Animals intravenously dosed with Nanomerics’ MET - lomustine formulations showed significantly improved survival rates when compared to the drug in solution and the effect of the drug on the bone marrow was comparable to the drug in solution.

Meet Nanomerics at JPMorgan/Biotech Showcase

Nanomerics’ CSO, Professor Ijeoma Uchegbu will be at Biotech Showcase in January 2016 (11th - 13th January 2016). This meeting is colocated with the JP Morgan Healthcare Conference in San Francisco. Please contact us, if you would like to meet with Nanomerics in San Francisco.

Meet Nanomerics at APS PharSci 2015

Nanomerics CEO Prof A. Schatzlein will be presenting latest results of the development of MET nano-enabled therapies at the annual APS PharmSci Meeting.
The conference, the 6th of this series, will be held from the 6th 7th - 9th September 2015, at the East Midlands Conference Centre, Nottingham at Nottingham.
Prof Schatzlein will be presenting in the BSNM Nanomedicines and Biotherapeutics session.

Pages